Blockade of the Programmed Death 1 (PD-1)/PD-1 Ligand (PD-L1) immune checkpoint axis with monoclonal antibodies is now a widespread therapeutic strategy across many cancers, including renal cell (1) and urothelial carcinomas (2) (RCC and UC). This evidence concerns the gene CD274 and renal cell adenocarcinoma.